Evidence map›Paper›PMID 38519525›Full record

Trial reportNature communications2024

Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.

Emily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, Margaret von Mehren, Naomi B Haas, Merrick I Ross, Lynn T Dengel, Craig L Slingluff

Open access · goldAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  6. Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Emily K NinmerDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA, USA.
Hong ZhuDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0001-8562-3351
Kimberly A Chianese-BullockDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0001-8676-3671
Margaret von MehrenFox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6158-890X
Naomi B HaasFox Chase Cancer Center, Philadelphia, PA, USA.
Merrick I RossDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7787-0421
Lynn T DengelDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA, USA.
Craig L SlingluffDepartment of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, VA, USA. cls8h@uvahealth.org.ORCID http://orcid.org/0000-0002-6664-4373
University of Virginia · USFox Chase Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk MelanomaR01CA118386 · NCI · UNIVERSITY OF VIRGINIA · PI SLINGLUFF, CRAIG LEE · 2006 to 2010
$1.8M
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA118386
6 · The paper itself

Abstract

The critical roles of CD4

Indexed as

Cancer VaccinesMelanomaAdjuvants, ImmunologicCD8-Positive T-LymphocytesFemaleHumansMalePeptidesAdjuvants, ImmunologicCancer VaccinesPeptides

Identifiers

PMID38519525
PMCPMC10959948
OpenAlexW4393071356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.